Paul Fronstin, director of Health Benefits Research at EBRI, discussed ERISA and trends in employer self-insurance during a ...

New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.

Whether this proposed rule actually has any impact remains to be seen, especially with a new administration led by Donald ...

CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is ...

The Stanford medical school professor, the expected pick for the top job at the National Institutes of Health, has been a ...

Seemal Desai, M.D., FAAD, discusses how treatment safety and effectiveness must be carefully evaluated through monitoring ...

Paul Fronstin, director of Health Benefits Research at EBRI, spoke with MHE about the challenges employers face in ...

The Institute for Clinical and Economic Review (ICER) has announced plans to assess the clinical efficacy and value of ...

Greg Baker, CEO of AffirmedRx, shared with MHE editors how the company is addressing ongoing challenges in the pharmacy ...

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...